Paris - Delayed Quote EUR

MedinCell S.A. (MEDCL.PA)

28.44 -0.12 (-0.42%)

At close: November 6 at 5:35:21 PM GMT+1

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Medincell Announces New Publication Date for Its Half-Year Financial Result (April 1st – September 30, 2026)

Business Wire 24d ago

MEDCL.PA
-0.42%
Medincell Announces New Publication Date for Its Half-Year Financial Result (April 1st – September 30, 2026)

Business Wire 24d ago

MEDCL.PA
-0.42%
Medincell Brings Total Non-Dilutive Financing Secured Since July 2026 to €41.8 Million with an Additional €13.8 Million Loan

Business Wire 25d ago

MEDCL.PA
-0.42%
Medincell Brings Total Non-Dilutive Financing Secured Since July 2026 to €41.8 Million with an Additional €13.8 Million Loan

Business Wire 25d ago

MEDCL.PA
-0.42%
Medincell Announces Resumption of Trading in Its Shares on Euronext Paris as of 2:45pm

Business Wire 30d ago

MEDCL.PA
-0.42%
Medincell Achieves Major Milestone with U.S. FDA Approval of WELTRUZA™ (olanzapine)

Business Wire 30d ago

MEDCL.PA
-0.42%
TEVA
Medincell Achieves Major Milestone with U.S. FDA Approval of WELTRUZA™ (olanzapine)

Business Wire 30d ago

MEDCL.PA
-0.42%
TEVA
Medincell Announces the Temporary Suspension of Trading in Its Shares on Euronext Paris

Business Wire 30d ago

MEDCL.PA
-0.42%
Medincell Extends Remote Voting Deadline for its Annual General Meeting Until 3:00 p.m. Today

Business Wire 1mo ago

MEDCL.PA
-0.42%
Medincell to Participate in Upcoming Investor Conferences

Business Wire 1mo ago

MEDCL.PA
-0.42%
Medincell to Participate in Upcoming Investor Conferences

Business Wire 1mo ago

MEDCL.PA
-0.42%
Medincell Appoints Edna Venneker, MD, as Chief Medical Officer

Business Wire 2mo ago

MEDCL.PA
-0.42%

Performance Overview

Return	MEDCL.PA	CAC 40 (^FCHI)
YTD	+12.86%	-0.13%
1-Year	-10.11%	+2.19%
3-Year	+398.95%	+16.04%

U.S. markets closed

MedinCell S.A. (MEDCL.PA)

Medincell Announces New Publication Date for Its Half-Year Financial Result (April 1st – September 30, 2026)

Medincell Announces New Publication Date for Its Half-Year Financial Result (April 1st – September 30, 2026)

Medincell Brings Total Non-Dilutive Financing Secured Since July 2026 to €41.8 Million with an Additional €13.8 Million Loan

Medincell Brings Total Non-Dilutive Financing Secured Since July 2026 to €41.8 Million with an Additional €13.8 Million Loan

Medincell Announces Resumption of Trading in Its Shares on Euronext Paris as of 2:45pm

Medincell Achieves Major Milestone with U.S. FDA Approval of WELTRUZA™ (olanzapine)

Medincell Achieves Major Milestone with U.S. FDA Approval of WELTRUZA™ (olanzapine)

Medincell Announces the Temporary Suspension of Trading in Its Shares on Euronext Paris

Medincell Extends Remote Voting Deadline for its Annual General Meeting Until 3:00 p.m. Today

Medincell to Participate in Upcoming Investor Conferences

Medincell to Participate in Upcoming Investor Conferences

Medincell Appoints Edna Venneker, MD, as Chief Medical Officer